IcoSema的重大进展：来自COMBINE 3的新数据铺平了道路。 - Suppr

IcoSema's leap forward: new data from COMBINE 3 paves the way.

作者信息

Seetharaman Rajmohan

机构信息

Department of Pharmacology, 76626 MGM Medical College and Hospital, Nerul, MGM Institute of Health Sciences (MGMIHS) , Navi Mumbai, India.

出版信息

J Basic Clin Physiol Pharmacol. 2024 Oct 2;35(6):323-324. doi: 10.1515/jbcpp-2024-0157. eCollection 2024 Nov 1.

DOI:10.1515/jbcpp-2024-0157

PMID:39352773

Abstract

摘要

相似文献

IcoSema's leap forward: new data from COMBINE 3 paves the way.IcoSema的重大进展：来自COMBINE 3的新数据铺平了道路。

J Basic Clin Physiol Pharmacol. 2024 Oct 2;35(6):323-324. doi: 10.1515/jbcpp-2024-0157. eCollection 2024 Nov 1.

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.成人2型糖尿病患者中每周一次IcoSema与每周一次司美格鲁肽的比较：COMBINE 2随机临床试验

Diabetologia. 2025 Apr;68(4):739-751. doi: 10.1007/s00125-024-06348-5. Epub 2025 Jan 17.

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.一项系统文献综述和网状荟萃分析：比较既往接受基础胰岛素治疗的2型糖尿病患者中，每周一次司美格鲁肽与其他胰高血糖素样肽-1（GLP-1）受体激动剂的疗效

Diabetes Ther. 2018 Jun;9(3):1233-1251. doi: 10.1007/s13300-018-0428-y. Epub 2018 Apr 30.

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.每周一次胰高血糖素样肽-1受体激动剂的血糖疗效、体重影响及安全性

J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S14-S29. doi: 10.18553/jmcp.2018.24.9-a.s14.

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.每周一次的胰高血糖素样肽-1受体激动剂度拉糖肽作为二甲双胍或二甲双胍加胰岛素促泌剂的附加治疗用于肥胖症和2型糖尿病的临床疗效及安全性

J Clin Med. 2021 Mar 2;10(5):985. doi: 10.3390/jcm10050985.

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.GLP-1 受体激动剂在 2 型糖尿病治疗中的应用——最新进展。

Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.

Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.GLP-1RA 治疗伴有或不伴有胰岛素的 2 型糖尿病患者的真实世界血糖控制情况。

J Manag Care Spec Pharm. 2017 Mar;23(3):267-275. doi: 10.18553/jmcp.2017.16334. Epub 2017 Feb 6.

J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S30-S41. doi: 10.18553/jmcp.2018.24.9-a.s30.

Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.每周一次的胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽激动剂与每周一次胰岛素治疗2型糖尿病的疗效和安全性比较：一项随机对照试验的网状Meta分析

Biomedicines. 2024 Aug 23;12(9):1943. doi: 10.3390/biomedicines12091943.

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.一项系统文献综述和网状荟萃分析：比较在既往接受1-2种口服抗糖尿病药物治疗的2型糖尿病患者中，每周一次的司美格鲁肽与其他胰高血糖素样肽-1（GLP-1）受体激动剂的疗效。

Diabetes Ther. 2018 Jun;9(3):1149-1167. doi: 10.1007/s13300-018-0424-2. Epub 2018 Apr 19.

引用本文的文献

Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors.胰高血糖素样肽-1受体类似物和二肽基肽酶-4抑制剂潜在心脏代谢效应的分子见解

Int J Mol Sci. 2025 Jul 15;26(14):6777. doi: 10.3390/ijms26146777.

Newer Insulin Preparations and Insulin Analogs.新型胰岛素制剂与胰岛素类似物。

Cureus. 2024 Nov 27;16(11):e74593. doi: 10.7759/cureus.74593. eCollection 2024 Nov.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

IcoSema's leap forward: new data from COMBINE 3 paves the way.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献